Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes
Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. I E Kelly , T S Han , K Walsh and M E Lean Department of Human Nutrition, University of Glasgow, Glasgow Royal Infirmary, Scotland, U.K. Abstract OBJECTIVE: To examine the effects of a thiazoli...
Saved in:
Published in | Diabetes care Vol. 22; no. 2; pp. 288 - 293 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
Alexandria, VA
American Diabetes Association
01.02.1999
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes.
I E Kelly ,
T S Han ,
K Walsh and
M E Lean
Department of Human Nutrition, University of Glasgow, Glasgow Royal Infirmary, Scotland, U.K.
Abstract
OBJECTIVE: To examine the effects of a thiazolidinedione (600 mg troglitazone) insulin-sensitizing treatment on total body
fat measured by underwater weighing, on intra- and extra-abdominal fat mass using magnetic resonance imaging (MRI), and on
anthropometric measures. RESEARCH DESIGN AND METHODS: Type 2 diabetic outpatients were studied in a double-blind randomized
trial carried out at Glasgow Royal Infirmary, Scotland. RESULTS: Groups who received troglitazone (8 men, 3 women) and placebo
(8 men, 2 women) were well matched for age, BMI, total body fat percentage by underwater weighing, and intra-abdominal fat
(kilograms) by MRI. After 12 weeks, body weight changes in the troglitazone group (mean +0.66 kg [95% CI -0.71 to 2.04], P
= 0.31) and the placebo group (mean +0.25 kg [-0.64 to 1.13], P = 0.55) were not statistically different. Changes in total
body fat with troglitazone (mean +1.02% body wt [-1.13 to 3.17], P = 0.32) and placebo (mean -0.54% body wt [-1.68 to 0.59],
P = 0.31) were not significantly different. There was, however, a decrease in intra-abdominal fat mass in the troglitazone-treated
group (mean -0.47 kg [-0.79 to -0.13], P = 0.01), and this was significantly different (P = 0.03) from placebo treatment (mean
-0.41 kg [-0.77 to -0.05]). CONCLUSIONS: Treatment with the thiazolidinedione troglitazone in human patients with type 2 diabetes
decreases intra-abdominal fat mass but does not affect total body fat or weight. This potentially valuable effect points to
a differential action on insulin sensitivity in different adipose tissue depots. |
---|---|
Bibliography: | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 ObjectType-News-3 content type line 23 |
ISSN: | 0149-5992 1935-5548 |
DOI: | 10.2337/diacare.22.2.288 |